Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Next Previous
Trial Profile

A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabocemagene autoficel (Primary)
  • Indications Epidermolysis bullosa dystrophica
  • Focus Adverse reactions
  • Sponsors Castle Creek Pharmaceuticals

Most Recent Events

  • 06 Feb 2023 Status changed from active, no longer recruiting to discontinued.
  • 25 Mar 2020 According to a Castle Creek Pharmaceuticals media release, results of this trial were presented at the inaugural World Congress on Epidermolysis Bullosa held in London during January of 2020.
  • 25 Mar 2020 Results presented in a Castle Creek Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top